Cardio Diagnostics (NASDAQ:CDIO) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Cardio Diagnostics (NASDAQ:CDIO) issued its earnings results on Monday. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07, Zacks reports. Cardio Diagnostics had a negative return on equity of 415.33% and a negative net margin of 34,911.87%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.13 million.

Cardio Diagnostics Stock Up 4.0 %

CDIO traded up $0.02 during midday trading on Wednesday, reaching $0.44. 9,362 shares of the company’s stock were exchanged, compared to its average volume of 700,399. Cardio Diagnostics has a one year low of $0.17 and a one year high of $3.56. The business has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.99.

Wall Street Analysts Forecast Growth

Separately, Benchmark boosted their price target on shares of Cardio Diagnostics from $1.35 to $2.00 and gave the company a “speculative buy” rating in a report on Thursday, June 6th.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.